Amgen and Roche settle EPO dispute
29 December 2009
Nancy Faigen
The five-year US patent infringement dispute between
Amgen and
Roche concerning Amgen's patents on recombinant erythropoietin (EPO) has come to an end. Under a stipulation signed by both parties, a federal judge in Boston has entered final judgement and permanently enjoined Roche from infringing on...
Please Login to read the full article.
29 December 2009
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: House adopts patent reform, but fee change could be trouble for Senate
- US Capitol Capsule: Federal shutdown averted, but spending reductions could spell trouble for expensive drugs
- Renamed Lipoxen turns to Russia to derisk biotech development
- US Capitol Capsule: Court rulings in gene patent, stem cell cases provide new hope for biopharma
COMMENT
Other Informa Comment
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
